Neurotrope Financial Statements (NTRP)
|
|
|
|
Report date
|
|
|
31.12.2021 |
31.12.2022 |
29.02.2024 |
29.05.2025 |
29.05.2026 |
|
14.01.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1.65 |
0.383 |
|
0.501 |
3.72 |
|
2.18 |
|
Operating Income, bln rub |
|
|
-8.48 |
-4.95 |
|
-8.41 |
-15.9 |
|
-14.1 |
|
EBITDA, bln rub |
? |
|
-7.28 |
-4.24 |
|
-7.70 |
-14.8 |
|
-12.8 |
|
Net profit, bln rub |
? |
|
-7.38 |
-5.03 |
|
-10.1 |
-15.9 |
|
-15.2 |
|
|
OCF, bln rub |
? |
|
|
|
-5.73 |
-5.08 |
-4.56 |
|
-4.40 |
|
CAPEX, bln rub |
? |
|
|
|
1.03 |
0.535 |
0.000 |
|
0.448 |
|
FCF, bln rub |
? |
|
|
|
-6.76 |
-5.61 |
-4.56 |
|
-4.24 |
|
Dividend payout, bln rub
|
|
|
|
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
0.00% |
0.00% |
|
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
|
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
9.57 |
4.98 |
|
8.42 |
14.0 |
|
14.6 |
|
Cost of production, bln rub |
|
|
0.560 |
0.355 |
|
0.498 |
3.06 |
|
1.77 |
|
R&D, bln rub |
|
|
0.891 |
0.551 |
|
0.843 |
0.000 |
|
0.000 |
|
Interest expenses, bln rub |
|
|
0.011 |
0.007 |
|
0.000 |
1.11 |
|
1.17 |
|
|
Assets, bln rub |
|
|
13.8 |
5.70 |
5.09 |
9.94 |
13.1 |
|
14.4 |
|
Net Assets, bln rub |
? |
|
12.9 |
5.07 |
3.13 |
7.37 |
5.37 |
|
6.28 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.828 |
0.568 |
3.39 |
|
4.10 |
|
Cash, bln rub |
|
|
11.4 |
2.85 |
0.324 |
1.06 |
1.70 |
|
2.43 |
|
Net debt, bln rub |
|
|
-11.4 |
-2.85 |
0.50 |
-0.49 |
1.69 |
|
1.67 |
|
|
Ordinary share price, rub |
|
|
36.8 |
|
2.99 |
3.98 |
|
|
2.21 |
|
Number of ordinary shares, mln |
|
|
0.491 |
0.525 |
|
4.57 |
8.93 |
|
8.97 |
|
|
Market cap, bln rub |
|
|
18 |
0 |
0 |
18 |
0 |
|
20 |
|
EV, bln rub |
? |
|
7 |
-3 |
1 |
18 |
2 |
|
21 |
|
Book value, bln rub |
|
|
12 |
4 |
0 |
4 |
-2 |
|
-1 |
|
|
EPS, rub |
? |
|
-15.0 |
-9.59 |
|
-2.22 |
-1.78 |
|
-1.70 |
|
FCF/share, rub |
|
|
0.00 |
0.00 |
|
-1.23 |
-0.51 |
|
-0.47 |
|
BV/share, rub |
|
|
24.3 |
7.52 |
|
0.89 |
-0.22 |
|
-0.07 |
|
|
EBITDA margin, % |
? |
|
-440.7% |
-1 108% |
|
-1 536% |
-398.7% |
|
-587.0% |
|
Net margin, % |
? |
|
-447.1% |
-1 315% |
|
-2 018% |
-428.3% |
|
-698.5% |
|
FCF yield, % |
? |
|
0.00% |
|
0.00% |
-30.9% |
|
|
-21.4% |
|
ROE, % |
? |
|
-57.4% |
-99.2% |
0.00% |
-137.4% |
-296.1% |
|
-242.7% |
|
ROA, % |
? |
|
-53.4% |
-88.2% |
0.00% |
-101.9% |
-121.7% |
|
-105.6% |
|
|
P/E |
? |
|
-2.45 |
0.00 |
|
-1.80 |
0.00 |
|
-1.30 |
|
P/FCF |
|
|
|
|
0.00 |
-3.24 |
0.00 |
|
-4.67 |
|
P/S |
? |
|
10.9 |
0.00 |
|
36.2 |
0.00 |
|
9.09 |
|
P/BV |
? |
|
1.52 |
0.00 |
0.00 |
4.47 |
0.00 |
|
-30.1 |
|
EV/EBITDA |
? |
|
-0.91 |
0.67 |
|
-2.30 |
-0.11 |
|
-1.68 |
|
Debt/EBITDA |
|
|
1.57 |
0.67 |
|
0.06 |
-0.11 |
|
-0.13 |
|
|
R&D/CAPEX, % |
|
|
|
|
0.00% |
157.7% |
|
|
0 |
|
|
CAPEX/Revenue, % |
|
|
0.00% |
0.00% |
|
106.6% |
0.00% |
|
20.5% |
|
| Neurotrope shareholders |
